Related Experiment Video
Updated: Nov 15, 2025
10:55
Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
262
Begelomab for severe refractory dermatomyositis: A case report.
Rebecca De Lorenzo1, Clara Sciorati2, Antonella Monno2
1Università Vita-Salute San Raffaele.
Medicine
|March 3, 2021
Summary
This study shows that blocking dipeptidyl peptidase-4 (DPP-4)/cluster of differentiation 26 (CD26) with a monoclonal antibody improved refractory idiopathic inflammatory myopathy (IIM) symptoms. The treatment was safe and effective for this challenging condition.
Area of Science:
- Immunology
- Rheumatology
- Dermatology
Background:
- Idiopathic inflammatory myopathies (IIM) are challenging to treat due to incomplete understanding of underlying molecular mechanisms.
- Severe refractory IIM cases often lack effective therapeutic options.
Observation:
- A patient with refractory dermatomyositis (DM) presented with muscle weakness, skin ulcerations, dysphagia, and recurrent intestinal vasculitis.
- Standard treatments including steroids, immunosuppressants, and rituximab failed to control the disease.
- DPP-4/CD26 expression was noted in the patient's affected skin and muscle tissues.
Findings:
- Treatment with begelomab, a monoclonal antibody targeting DPP-4/CD26, led to resolution of dysphagia, skin lesions, and intestinal vasculitis.
- The patient reported significant improvement in quality of life following the intervention.
Implications:
- DPP-4/CD26 blockade shows promise as a safe and effective therapeutic strategy for refractory DM.
- Targeting DPP-4/CD26, which is involved in T cell activation, may offer a novel approach for managing IIM.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
317
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
317
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
290
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
290
01:29Inflammatory Bowel Disease IV: Pharmacological Management
291
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
291
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
293
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
293
01:20Myasthenia Gravis: Overview and Treatment
2.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K